Skip to main content Back to Top


Pantoprazole Injection

Products Affected - Description

    • Protonix IV, Pfizer, 40 mg, vial, 10 count, NDC 00008-0923-55
    • Protonix IV, Pfizer, 40 mg, vial, 25 count, NDC 00008-0923-60
    • Pantoprazole lyophilized powder for solution for injection, AuroMedics, 40 mg, vial, 10 count, NDC 55150-0202-10
    • Pantoprazole lyophilized powder for injection, Hikma, 40 mg, vial, 10 count, NDC 00143-9284-10

Reason for the Shortage

    • AuroMedics has pantoprazole injection on shortage due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has Protonix injection on shortage due to manufacturing delays.

Available Products

    • Pantoprazole powder for solution for injection, Sun Pharma, 40 mg, vial, 10 count, NDC 62756-0129-44

Estimated Resupply Dates

    • AuroMedics has pantoprazole 40 mg vials on intermittent back order and the company is releasing product as it becomes available.
    • Hikma has pantoprazole 40 mg vials on allocation.
    • Pfizer has Protonix 25 mg vials in 25 count and 40 mg vials available in limited supply.


Updated October 21, 2019 by Rachael Freeman, PharmD, BCPS. Created March 28, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins